ATE490276T1 - Humanisierte antikörper gegen icam-1, deren herstellung und verwendungen - Google Patents

Humanisierte antikörper gegen icam-1, deren herstellung und verwendungen

Info

Publication number
ATE490276T1
ATE490276T1 AT02798403T AT02798403T ATE490276T1 AT E490276 T1 ATE490276 T1 AT E490276T1 AT 02798403 T AT02798403 T AT 02798403T AT 02798403 T AT02798403 T AT 02798403T AT E490276 T1 ATE490276 T1 AT E490276T1
Authority
AT
Austria
Prior art keywords
humanized antibodies
production
antibodies against
against icam
antibodies
Prior art date
Application number
AT02798403T
Other languages
German (de)
English (en)
Inventor
Fang Fang
Guang-Xiang Luo
Lori Kohlstaedt
Catherine Charles
Original Assignee
Perlan Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perlan Therapeutics Inc filed Critical Perlan Therapeutics Inc
Application granted granted Critical
Publication of ATE490276T1 publication Critical patent/ATE490276T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02798403T 2001-07-19 2002-07-19 Humanisierte antikörper gegen icam-1, deren herstellung und verwendungen ATE490276T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/910,483 US20030035798A1 (en) 2000-08-16 2001-07-19 Humanized antibodies
PCT/US2002/023002 WO2003035696A2 (en) 2001-07-19 2002-07-19 Humanized antibodies against icam-1, their production and uses

Publications (1)

Publication Number Publication Date
ATE490276T1 true ATE490276T1 (de) 2010-12-15

Family

ID=25428849

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02798403T ATE490276T1 (de) 2001-07-19 2002-07-19 Humanisierte antikörper gegen icam-1, deren herstellung und verwendungen

Country Status (10)

Country Link
US (4) US20030035798A1 (enExample)
EP (2) EP2336186A1 (enExample)
JP (3) JP4516312B2 (enExample)
AT (1) ATE490276T1 (enExample)
AU (3) AU2002363027C1 (enExample)
CA (2) CA2793019A1 (enExample)
DE (1) DE60238485D1 (enExample)
DK (1) DK1414861T3 (enExample)
ES (1) ES2356896T3 (enExample)
WO (1) WO2003035696A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE293994T1 (de) * 1997-12-01 2005-05-15 Fang Fang Multivalente rekombinante antikörper zur behandlung von hrv infektionen
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
WO2003062370A2 (en) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
WO2005086568A2 (en) * 2004-01-26 2005-09-22 Morphosys Ag Anti-icam-1 human antibodies and uses thereof
TW200616662A (en) * 2004-09-10 2006-06-01 Wyeth Corp Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
US7462698B2 (en) 2005-07-22 2008-12-09 Y's Therapeutics Co., Ltd. Anti-CD26 antibodies and methods of use thereof
GB2430030B (en) * 2005-09-07 2009-04-01 Ethicon Inc Diagnostic markers of wound infection III
GB0525214D0 (en) * 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
BRPI1014089A2 (pt) * 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
DK2417156T3 (en) 2009-04-07 2015-03-02 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2010146550A1 (en) 2009-06-18 2010-12-23 Pfizer Inc. Anti notch-1 antibodies
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
GB2482536B (en) 2010-08-05 2013-07-24 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
GB2482535A (en) * 2010-08-05 2012-02-08 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
LT2647707T (lt) 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
JP6016800B2 (ja) 2010-12-15 2016-10-26 ワイス・エルエルシー 抗ノッチ１抗体
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
JP5764677B2 (ja) 2011-02-28 2015-08-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗原結合タンパク質
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
RU2016115866A (ru) 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
US11505605B2 (en) * 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CH668554A5 (de) 1984-04-09 1989-01-13 Sandoz Ag Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung.
EP0169146A3 (en) 1984-07-20 1988-07-20 Merck & Co. Inc. Monoclonal antibodies directed against the cellular receptor of human rhinovirus
US4698420A (en) * 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
US5077195A (en) * 1985-03-01 1991-12-31 Board Of Reagents, The University Of Texas System Polypeptides complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known and methods of design therefor
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
ES2039203T3 (es) 1985-11-22 1993-09-16 Takeda Chemical Industries, Ltd. Composicion de liposomas.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP2666345B2 (ja) 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
US5565550A (en) * 1987-05-04 1996-10-15 Dana Farber Cancer Institute Antibodies to ICAM-2, and fragments thereof
US5284931A (en) * 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
EP0289949B1 (en) 1987-05-04 1995-10-04 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE190355T1 (de) 1988-09-06 2000-03-15 Xoma Corp Genexpressions-elemente und herstellung von chimären maus-mensch-antikörpern
ES2077572T3 (es) 1988-09-28 1995-12-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular, y sus ligandos de fijacion.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0448650A4 (en) 1989-02-01 1992-05-13 The General Hospital Corporation Herpes simplex virus type i expression vector
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
DE69000248T2 (de) 1989-03-09 1993-01-07 Boehringer Ingelheim Pharma Verwendung von interzellularen adhaesions-molekuelen und deren bindungsliganden bei der behandlung von asthma.
US5081584A (en) * 1989-03-13 1992-01-14 United States Of America Computer-assisted design of anti-peptides based on the amino acid sequence of a target peptide
EP0404003A3 (en) 1989-06-19 1991-10-16 Xoma Corporation Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen
US5324510A (en) * 1989-09-01 1994-06-28 Boehringer Ingelheim Pharmaceuticals, Inc. Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
KR910009285A (ko) 1989-11-13 1991-06-28 원본미기재 Hiv 항원에 특이적인 키메라형 생쥐-인간항체
EP0453554A4 (en) 1989-11-13 1993-02-17 Xoma Corporation Chimeric mouse human antibodies with specificity to hiv antigens
AU634314B2 (en) 1989-11-13 1993-02-18 Green Cross Corporation, The Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
EP0459577A3 (en) * 1990-06-01 1992-08-05 Merck & Co. Inc. Microbially expressed portions of a monoclonal antibody block rhinovirus attachment to cell receptors
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
JPH06500923A (ja) 1990-09-21 1994-01-27 カイロン　コーポレイション パッケージング細胞
US5582996A (en) * 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE69131908T3 (de) 1991-02-19 2008-04-03 Oxford Biomedica (Uk) Ltd. Viruspartikel mit veraendertem wirtspektrum
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5223396A (en) * 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US6027725A (en) * 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
WO1993015210A1 (en) 1992-01-23 1993-08-05 Merck Patent Gmbh Monomeric and dimeric antibody-fragment fusion proteins
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
WO1993019660A1 (en) 1992-04-03 1993-10-14 Baylor College Of Medicine Gene therapy using the intestine
US6329507B1 (en) * 1992-08-21 2001-12-11 The Dow Chemical Company Dimer and multimer forms of single chain polypeptides
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5832448A (en) * 1996-10-16 1998-11-03 Health Hero Network Multiple patient monitoring system for proactive health management
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
US5491074A (en) * 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
DE9390311U1 (de) * 1993-05-18 1996-05-09 I.D.M. Immuno-Designed Molecules, Paris Neue Makrophagen mit Eignung als Wirkstoffe von pharmazeutischen Zusammensetzungen
AU7353494A (en) 1993-11-12 1995-05-29 Case Western Reserve University Episomal expression vector for human gene therapy
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US5731172A (en) 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
GB9409768D0 (en) * 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
US5721340A (en) * 1994-11-28 1998-02-24 The Wistar Institute Of Anatomy & Biology p53 proteins with altered tetramerization domains
US5573925A (en) * 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
US5632448A (en) * 1995-01-25 1997-05-27 Ransburg Corporation Rotary powder applicator
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
JPH11508126A (ja) * 1995-05-23 1999-07-21 モルフォシス ゲゼルシャフト ファー プロテインオプティマイルング エムベーハー 多量体タンパク質
US6110456A (en) 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
JP2783276B2 (ja) * 1995-07-04 1998-08-06 日本電気株式会社 半導体装置の製造方法
US5942433A (en) 1995-07-31 1999-08-24 The United States Of America As Represented By The Department Of Health And Human Services Extension of a protein-protein interaction surface to inactivate the function of a cellular protein
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU715914B2 (en) 1995-12-22 2000-02-10 Baxter Biotech Technology S.A.R.L. Globins containing binding domains
IL126314A (en) * 1996-03-25 2003-07-31 Northwest Biotherapeutics Inc Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostate specific membrane antigen (psma)
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
US6096291A (en) 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
EP2338915A3 (en) * 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
ATE293994T1 (de) 1997-12-01 2005-05-15 Fang Fang Multivalente rekombinante antikörper zur behandlung von hrv infektionen
JPH11228446A (ja) * 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
US20020165153A1 (en) 1998-04-06 2002-11-07 Peter Angel Transcription factors and their use
US20020102604A1 (en) * 1999-12-08 2002-08-01 Milne Edwards Jean-Baptiste Dumas Full-length human cDNAs encoding potentially secreted proteins
US5965712A (en) * 1998-06-19 1999-10-12 Virginia Commonwealth University LZ-CD23 chimera for inhibition of IgE-mediated allergic disease
ES2265693T3 (es) * 1998-10-16 2007-02-16 Biogen Idec Ma Inc. Proteinas de fusion con interferon-beta y usos.
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
ATE477273T1 (de) * 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
CA2377513A1 (en) 1999-06-25 2001-01-04 Universitat Zurich Hetero-associating coiled-coil peptides
IL148549A0 (en) 1999-09-17 2002-09-12 Genzyme Transgenics Corp Subunit optimized fusion proteins
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
ES2332872T3 (es) 2000-04-28 2010-02-15 Planet Biotechnology, Inc. Inmunoadhesina para la prevencion de la infeccion por rinovirus.
WO2003062370A2 (en) * 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
JP4236000B2 (ja) 2003-09-25 2009-03-11 元気株式会社 ３次元画像処理装置、３次元画像処理方法及びプログラム

Also Published As

Publication number Publication date
CA2454361C (en) 2013-01-08
AU2008258214A1 (en) 2009-01-15
AU2002363027C1 (en) 2009-04-30
US20110044976A1 (en) 2011-02-24
AU2012203365A1 (en) 2012-06-28
WO2003035696A3 (en) 2003-11-27
JP2013116119A (ja) 2013-06-13
US20030035798A1 (en) 2003-02-20
CA2793019A1 (en) 2003-05-01
AU2008258214B2 (en) 2012-03-08
US20140308269A1 (en) 2014-10-16
WO2003035696A2 (en) 2003-05-01
EP2336186A1 (en) 2011-06-22
CA2454361A1 (en) 2003-05-01
AU2002363027B2 (en) 2008-09-18
EP1414861B1 (en) 2010-12-01
EP1414861A2 (en) 2004-05-06
JP2005524385A (ja) 2005-08-18
JP4516312B2 (ja) 2010-08-04
US8586712B2 (en) 2013-11-19
US20070071742A1 (en) 2007-03-29
JP2009183303A (ja) 2009-08-20
DK1414861T3 (da) 2011-03-21
DE60238485D1 (de) 2011-01-13
US7696324B2 (en) 2010-04-13
ES2356896T3 (es) 2011-04-14

Similar Documents

Publication Publication Date Title
ATE490276T1 (de) Humanisierte antikörper gegen icam-1, deren herstellung und verwendungen
DE50303413D1 (de) Befestigungsmittel und Verfahren zu seiner Herstellung
DE60126099D1 (de) Kristallines und reines modafinil und verfahren zu seiner herstellung
ATE309196T1 (de) Verfahren zur herstellung von 3-aryloxy-3- arylpropylamine und deren zwischenprodukte
DE60013228D1 (de) Sorptionsfähige verbundwerkstoffe die unabhängig sind von aktivierungsbehandlungen und verfahren zur herstellung
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
DE69535133D1 (de) Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
ATE481108T1 (de) Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
DE50214717D1 (de) Und verfahren zu seiner herstellung
DE60317586D1 (de) Verfahren zur Herstellung von mehrschichtigen, halbleitenden Nanopartikeln und und die nach diesem Verfahren erhaltenen mehrschichtigen, halbleitenden Nanopartikel
ATE407987T1 (de) Neue mesogene, verfahren zu deren herstellung und verwendung
ATE304062T1 (de) Vollnarbiges rindnappaleder und verfahren zur herstellung desselben
EP0588351A3 (en) Hard wear-resistant layer and process for its manufacture.
ATE388135T1 (de) Verfahren zur herstellung von 1,3-substituierte indene und aryl-annellierte azapolycyclische verbindungen
DE60323994D1 (de) Verfahren zur herstellung von 2-chlor-1,1,1,2,3,3,3-heptafluorpropan, hexafluorpropen und 1,1,1,2,3,3,3-heptafluorpropan
DE59914950D1 (de) Feldeffektgesteuerter transistor und verfahren zu dessen herstellung
DE60112136D1 (de) Verfahren zur Herstellung von 1-(2,5-Diaminophenyl)ethanol und dessen Verwendung für oxidative Färbeprozesse
DE60227517D1 (de) Verfahren zur herstellung von 10,11 dihydro 10 hydroxy 5h-dibenz/b,f/azepin-5-carbonsäureamid und 10,11 dihydro 10 oxo-5h-dibenz/b,f/azepin-5 carbonsäureamid
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
BRPI0411837A (pt) pirazolopirimidinas
DE60210184D1 (de) L-cystein herstellendes Bakterium und Verfahren zur Herstellung von L-cystein
DE60133586D1 (de) Kopfschieber und verfahren zu seiner herstellung
ATA5752001A (de) Kabelführung und verfahren zum herstellen derselben
DE60308388D1 (de) 5-androsten-3-olsteroidzwischenprodukte und verfahren zu deren herstellung
DE60116581D1 (de) Verfahren zur Fluorierung von 1,1,1,3,3-Pentachloropropan

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties